| P50 | author | Doo-Yeoun Cho | Q60311745 |
| P2093 | author name string | Euichaul Oh | |
| | Bom-Taeck Kim | |
| | Sukhyang Lee | |
| | Soo Kyung Bae | |
| | Jung Bae Park | |
| | Joeng Kee Lee | |
| | Soo Hyeon Bae | |
| | Yang-Weon Kim | |
| P2860 | cites work | Sarpogrelate treatment reduces restenosis after coronary stenting | Q28195521 |
| | The 5-HT2 receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients | Q28368134 |
| | Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity | Q30872988 |
| | Pharmacokinetics of selective serotonin reuptake inhibitors | Q33837768 |
| | Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with angina pectoris | Q34144541 |
| | Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin | Q34241704 |
| | In-vitro pharmacology of sarpogrelate and the enantiomers of its major metabolite: 5-HT2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat tail artery | Q34313846 |
| | The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. | Q34348446 |
| | The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus | Q34350682 |
| | Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies | Q34447046 |
| | Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. | Q34544828 |
| | Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10 | Q35287206 |
| | Therapeutic potentials of sarpogrelate in cardiovascular disease | Q35673144 |
| | Functions of 5-HT2A receptor and its antagonists in the cardiovascular system | Q35925916 |
| | Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia | Q36792630 |
| | The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects | Q39219864 |
| | A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer | Q39353969 |
| | The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations | Q39422300 |
| | Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers | Q42622887 |
| | Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes | Q42708698 |
| | Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans | Q43555133 |
| | Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity | Q44208902 |
| | Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling | Q44434675 |
| | Pharmacokinetics of a new once-daily controlled-release sarpogrelate hydrochloride compared with immediate-release formulation and the effect of food | Q44615221 |
| | Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans | Q46052063 |
| | Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers | Q46332841 |
| | Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery | Q46892256 |
| | Pharmacokinetic and pharmacodynamic interaction of nadolol with itraconazole, rifampicin and grapefruit juice in healthy volunteers. | Q50990638 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| | pharmacodynamics | Q725307 |
| P304 | page(s) | 256-263 | |
| P577 | publication date | 2014-09-30 | |
| P1433 | published in | Xenobiotica | Q1360678 |
| P1476 | title | Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers | |
| P478 | volume | 45 | |